Article Text

other Versions

PDF
Extended report
Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFκB signalling pathways
  1. Catherine Potter1,
  2. Heather J Cordell,
  3. Anne Barton3,
  4. Ann K Daly4,
  5. Kimme L Hyrich3,
  6. Derek A Mann5,
  7. Ann W Morgan6,
  8. Anthony G Wilson7,
  9. and the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS),
  10. John D Isaacs1
  1. 1Institute of Cellular Medicine, Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, UK
  2. 2Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, UK
  3. 3School of Translational Medicine, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, UK
  4. 4Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
  5. 5Liver Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
  6. 6NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, UK
  7. 7Section of Musculoskeletal Sciences, School of Medicine, University of Sheffield, Sheffield, UK
  1. Correspondence to Professor John D Isaacs, Musculoskeletal Research Group, Institute of Cellular Medicine, University of Newcastle, 4th Floor Catherine Cookson Building, Framlington Place, Newcastle upon Tyne NE2 4HH, UK; j.d.isaacs{at}ncl.ac.uk

Abstract

Objective To determine whether genetic variation within genes integral to the Toll-like receptor (TLR) and NFκB signalling systems, two cardinal regulators of inflammatory and immune responses, contributes towards the observed variation in response to tumour necrosis factor (TNF) blocking agents in patients with rheumatoid arthritis (RA).

Methods Pairwise-tagging single nucleotide polymorphisms (SNPs) spanning 24 candidate genes were selected and genotyped in a large UK cohort of patients receiving anti-TNF therapy for RA. Multivariate regression analyses were performed to test association between individual genotypes, under an additive model, and treatment response at 6 months' follow-up assessed using both the absolute change in 28-joint count Disease Activity Score (DAS28) and the European League Against Rheumatism (EULAR) response criteria. Analyses were performed across subgroups comprising etanercept-, infliximab- and infliximab/adalimumab-treated patients as well as the combined anti-TNF-treated cohort. p Values <0.05 were considered statistically significant.

Results A total of 187 SNPs were successfully genotyped and analysed in 909 patients. Eight SNPs spanning six genes demonstrated nominal evidence of association with response (DAS28) across the anti-TNF-treated subgroups, six of which were restricted to etanercept-treated patients. Twelve SNPs spanning nine genes demonstrated nominal evidence of association with treatment response (DAS28 and/or EULAR) across the combined anti-TNF cohort. These included SNPs mapping to MyD88 (rs7744) and CHUK (rs11591741), which were associated under each model applied (etanercept-treated and combined anti-TNF cohort analysis (DAS28 and EULAR)).

Conclusions Several SNPs mapping to the TLR and NFκB signalling systems demonstrated association with anti-TNF response as a whole and, in particular, with response to etanercept. Validation of these findings in an independent cohort is now warranted.

Statistics from Altmetric.com

Footnotes

  • Members of BRAGGSS are given in the online supplementary data.

  • Funding The authors thank JGW Patterson Foundation for funding this work. Work in Newcastle's Musculoskeletal Research Group is supported by the UK NIHR Biomedical Research Centre for Ageing and Age-related disease award to the Newcastle upon Tyne Hospitals NHS Foundation Trust

  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the UK Central Office of Research Ethics Committees (COREC) approval (04/Q1403/37).

  • Provenance and peer review Not commissioned; not externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.